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Introduction. There is a high incidence of nephrotic proteinuria in renal transplant
recipients, which is an accurate predictor of graft loss. Despite this, its histologic correlates
and prognostic implications are still not well characterized. We assessed the clinical and
histological correlates of kidney transplantation patients with nephrotic range proteinuria.
Methods. We have retrospectively analyzed clinical and histological data from 50 kidney
transplantation biopsy specimens from 44 renal transplant recipients with nephrotic range
proteinuria between 2006 and 2015. The median follow-up time was 93 months (range,
14 months to 190 months).
Results. The mean age of the patients was 45.2 13.7 years and our cohort included 86%
recipients of deceased-donor grafts. The maintenance immunosuppressive regimen
included calcineurin inhibitors in 68% and mammalian target of rapamycin inhibitors in
32% of patients. The average proteinuria was 6.9  3.8 g/d and 52% of patients
presented with nephrotic syndrome. The main histological findings were transplant
glomerulopathy (22%), de novo glomerular disease (22%), and recurrence of primary
disease (22%). Tubular atrophy and interstitial fibrosis was present in 78% of the biopsy
specimens. Thirty-one patients (62%) lost the graft at follow-up. There was no
statistically significant difference between the histologic diagnosis nor the proteinuria
levels and the outcome of the graft.
Conclusions. The main causes of nephrotic range proteinuria in patients undergoing
biopsy were transplant glomerulopathy, recurrence of the underlying disease, and de novo
glomerulonephritis. Nephrotic range proteinuria was related to a high rate of graft loss.*Address correspondence to Rita Leal, MD, Nephrology
Department, Centro Hospitalar e Universitário de Coimbra,
Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. E-mail:
rita.gcleal@gmail.comNEPHROTIC proteinuria in kidney transplant (KT)patients is one of the most accurate predictors of
graft loss and patients with nephrotic syndrome have a
5-year graft survival rate significantly lower than patients
without proteinuria [1,2]. The 2009 Kidney Disease:
Improving Global Outcomes (KDIGO) clinical practice
guidelines on KT suggest frequent measuring of urine
protein excretion and renal allograft biopsy for new-onset
proteinuria or unexplained nephrotic-range proteinuria
[3]. Unfortunately, histologic correlates and prognostic
implications of post-transplantation proteinuria are still
not well characterized and evidence-based therapies are
limited [4].7
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of KT patients with nephrotic range proteinuria in our center.
PATIENTS AND METHODS
An observational retrospective single-center study was performed
from January 1, 2006, to December 31, 2016. Among the 450 KT
biopsies performed during that period in our center, we selected allª 2017 Elsevier Inc. All rights reserved.
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Dowthe biopsy specimens of patients who presented 24-hour
proteinuria 3.5 g at the time of the biopsy. A total of 50 biopsy
specimens from 44 recipients were selected. The 2011 Banff clas-
sification for renal transplant biopsy was used for diagnostic
categorization.
Patient records were reviewed for clinical features, response to
treatment, and graft outcome. The median follow-up time was
93 months (range, 14 months to 190 months).
Remission was defined as protein excretion of less than 0.5 g/d for
2 consecutive assays.
Data was analyzed using SPSS statistics software (IBM SPSS Sta-
tistics for Windows, version 21, IBM Corp., Armonk, NY, USA).
Comparisons used the c2 test for categorical variables and Student t
test or the Mann-Whitney U test for continuous variables, as appro-
priate. Results were considered statistically significant at P < .05.RESULTS
Clinical Characteristics
The 44 recipients evaluated included 64% (N ¼ 32) males
with a mean age of 45.2  13.7 years. It was the first
transplant for 84% of the patients (N ¼ 42), and 86%
(N ¼ 43) received a cadaveric graft, of which 46% fulfilled
marginal donor criteria. Regarding immunosuppression,
induction with basiliximab was performed in 54% of the
recipients (N ¼ 27). The maintenance immunosuppressive
included calcineurin inhibitors in 68% and mammalian
target of rapamycin (mTOR) inhibitors in 32% of patients
(Table 1).Table 1. Demographic Characteristics, Immunosuppression and
Post-transplantation Events of the General Population
Demographic Features
Age (y) (mean  SD) 45.2  13.7
Male gender N ¼ 32, 64%
Cadaveric donor N ¼ 43, 86%
Expanded criteria donor N ¼ 23, 46%
BMI (kg/m2) (mean  SD) 25.3  3.8
Diabetes mellitus N ¼ 8, 16%
Hypertension N ¼ 30, 60%
Primary Kidney Disease
Undetermined N ¼ 15, 30%
Chronic glomerulonephritis (unspecified) N ¼ 14, 28%
Diabetic nephropathy N ¼ 4, 8%
IgA nephropathy N ¼ 4, 8%
Nephroangiosclerosis N ¼ 3, 6%
Focal segmental glomerulosclerosis N ¼ 3, 6%
Polycystic Kidney Disease N ¼ 3, 6%
Membranous nephropathy N ¼ 2, 4%
Type 1 primary hyperoxaluria N ¼ 2, 4%
HLA mismatches (mean  SD) 3.0  1.2
Maintenance Immunosuppression
Regimen including steroids N ¼ 40, 80%
Calcineurin inhibitors N ¼ 34, 68%
mTOR inhibitors N ¼ 15, 30%
Post-transplantation Clinical Events
Acute rejection N ¼ 6, 12%
Chronic rejection N ¼ 8, 16%
Previous infection with hospital admission N ¼ 5, 10%
Abbreviations: SD, standard deviation; BMI, body mass index; IgA,
immunoglobulin A; mTOR, mammalian target of rapamycin.
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and the mean creatinine value at the time of the biopsy was
2.53  1.14 mg/dL. The mean 24-hour proteinuria was 6.9 
3.8 g and 26 patients (52%) presented with concomitant
nephrotic syndrome. Regarding donor-specific HLA
antibodies, they were positive in 15 recipients at the time of
graft biopsy (30%).
Allograft Histology
The mean time post-transplantation at biopsy was
44 months (range, 24 months to 102.3 months). Histological
findings of the 50 biopsy specimens are displayed in Table 2.
The main primary histologic diagnoses were transplant
glomerulopathy, recurrent glomerular diseases, and de novo
glomerular diseases. Of the 11 patients with transplant
glomerulopathy, 7 presented with positive C4d staining and
donor-specific HLA antibodies (7 of 11, 64%) and were
diagnosed with chronic humoral rejection. Regarding de
novo glomerular diseases, 3 patients had undetermined
cause for primary chronic kidney disease, whereas the
others had chronic kidney disease due to nephroangio-
sclerosis (N ¼ 2), diabetic nephropathy (N ¼ 3), immuno-
globulin A (IgA) nephropathy (N ¼ 2), and membranous
nephropathy (N ¼ 1), with a different histological diagnosis
on the transplant biopsy.
Interstitial fibrosis and tubular atrophy with glomerular
sclerosis was present in 39 biopsy specimens (78%) but only
in 8 specimens represented the primary diagnosis in the
context of chronic allograft nephropathy.
Treatment
Maintenance therapy with angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers was performed
in 16 patients (32%) with chronic allograft nephropathy,Table 2. Findings in 50 Transplantation Biopsy Specimens in
44 Patients With Post-transplantation Nephrotic Proteinuria
Primary Diagnoses N %





Transplant glomerulopathy 11 22
De novo glomerular disease 11 22






FSGS þ IFTA 8 16
FSGS þ acute rejection 5 10
Other 4 8
Total 50 100
Abbreviations: IgA, immunoglobulin A; FSGS, focal segmental
glomerulosclerosis; GN, glomerulonephritis; IF, immunofluorescence; IFTA,
interstitial fibrosis and tubular atrophy.
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Dowand transplant glomerulopathy with important interstitial
fibrosis and tubular atrophy. Increased immunosuppression
was the approach in 18 patients (36%) with transplant
glomerulopathy, recurrent glomerular diseases, and de novo
glomerular diseases. Methylprednisolone pulses were per-
formed in 9 patients (18%) including acute rejection
imposed in chronic allograft nephropathy and de novo
glomerular diseases. Therapeutic plasma exchange was
performed in 5 patients (10%): 2 patients with antibody
mediated rejection and 3 patients with recurrent focal and
segmental sclerosis. Two patients received rituximab
including 1 patient with membranoproliferative glomerulo-
nephritis and 1 patient for chronic antibody mediated
rejection.
Outcome
The median follow-up time was 93 months (range,
14 months to 190 months). Complete remission of the
nephrotic proteinuria was observed in 5 patients (11%),
three of them with de novo glomerular disease and two with
recurrent glomerular disease. Thirty patients (68%) are
dialysis-dependent, and there were three deaths registered.
There was no difference between the immunosuppressive
regimen used and the levels of proteinuria. There was no
statistically significant difference between the histologic
diagnosis nor the proteinuria levels and the outcome of the
graft.
DISCUSSION
Previous studies report an average prevalence of 24-hour
proteinuria >3 g/24-hour in KT recipients of 15% [5e7].
The present study reports post-transplantation proteinuria
in 22.5% patients submitted to graft biopsies in a 10-year
period. This high incidence might be related to the study
design, as the general population includes patients under-
going biopsy, conditioning a selection bias.
Regarding etiology, the main histological findings in our
report are concordant with the existing literature: recurrent
glomerular diseases, de novo glomerulopathy, and trans-
plant glomerulopathy [4,7].
In the KT population, the evidence base for the man-
agement of proteinuria is lacking for most cases, but routine
monitoring of proteinuria as part of follow-up is recom-
mended. Renin-angiotensin-aldosterone system blockade
results in a significant reduction in proteinuria, but this
benefit is frequently accompanied by a significant reduction
in glomerular filtration rate and there is no evidence of
improved patient or graft survival [4]. Some studies have
noted an association between proteinuria and the use ofnloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hosp
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inhibitors [8]. We did not find any significant relation
between the use of mTOR inhibitors and the level of
proteinuria.
Our study reported a high rate of graft loss at time of
follow up (69%). This might be related to the high preva-
lence of interstitial fibrosis and tubular atrophy found in our
biopsy specimens, indicating chronic lesions regardless the
glomerular changes. Also, the time of follow up was very
variable and the majority of the patients were transplanted
for more than 5 years at the time of biopsy. Although pro-
teinuria is strongly associated with graft survival, other
factors, such as donor age, may be equally significant [4,5,9].CONCLUSION
In our report, the main causes of nephrotic range protein-
uria in patients undergoing biopsy were transplant glomer-
ulopathy, recurrence of the underlying disease, and de novo
glomerulonephritis. Nephrotic range proteinuria was
related to a high rate of graft loss.REFERENCES
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